• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者报告颏下脂肪分级量表和患者报告颏下脂肪影响量表的制定与验证。

Development and Validation of the Patient-Reported Submental Fat Rating Scale and the Patient-Reported Submental Fat Impact Scale.

机构信息

Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana.

SkinCare Physicians, Chestnut Hill, Massachusetts.

出版信息

Dermatol Surg. 2021 Apr 1;47(4):522-525. doi: 10.1097/DSS.0000000000002908.

DOI:10.1097/DSS.0000000000002908
PMID:33306491
Abstract

BACKGROUND

No validated assessment tools are available to evaluate patient-reported outcomes specifically related to submental fat (SMF).

OBJECTIVE

To develop and validate scales measuring the severity (Patient-Reported SMF Rating Scale [PR-SMFRS]) and psychological impact (Patient-Reported SMF Impact Scale [PR-SMFIS]) of SMF.

MATERIALS AND METHODS

A literature review, content validation interviews (concept elicitation [n = 29] and cognitive debriefing [n = 15]) in adults with SMF, and expert interviews (n = 3) were conducted to develop the PR-SMFRS and PR-SMFIS. Psychometric validity (acceptability, reliability, and validity) for the PR-SMFRS and PR-SMFIS was assessed using data from 1 phase 2 and 5 phase 3 ATX-101 studies in patients with excess SMF.

RESULTS

The PR-SMFRS was constructed as a single-item, 5-point rating of the SMF amount/size. The PR-SMFIS was constructed as a 6-item scale, with an 11-point numeric rating for each item. Both scales demonstrated acceptable psychometric properties (test-retest reliability and internal consistency). The anchor-based minimally important difference analysis suggests a 1-point improvement on the PR-SMFRS (scale of 0‒4) and a 3-point improvement on the PR-SMFIS (scale of 0‒10) represent clinically meaningful change.

CONCLUSION

The PR-SMFRS and PR-SMFIS are reliable, valid instruments for assessing the severity and psychosocial impact, respectively, of SMF and detecting clinically meaningful change with intervention.

摘要

背景

目前尚无经过验证的评估工具可用于评估与颏下脂肪(SMF)相关的患者报告结局。

目的

开发和验证用于评估 SMF 严重程度(患者报告的颏下脂肪严重程度评分[PR-SMFRS])和心理影响(患者报告的颏下脂肪影响评分[PR-SMFIS])的量表。

材料和方法

进行文献回顾、有 SMF 的成年人的内容验证访谈(概念发掘[n=29]和认知性访谈[n=15])以及专家访谈(n=3),以制定 PR-SMFRS 和 PR-SMFIS。使用来自 ATX-101 治疗颏下脂肪过多的 1 项 2 期和 5 项 3 期研究的数据评估 PR-SMFRS 和 PR-SMFIS 的心理测量学有效性(可接受性、信度和效度)。

结果

PR-SMFRS 构建为一个 5 分制的单项评分,用于评估 SMF 的数量/大小。PR-SMFIS 构建为一个 6 项量表,每项的数值评分范围为 11 分。这两个量表均具有可接受的心理测量学特性(重测信度和内部一致性)。基于锚定的最小重要差异分析表明,PR-SMFRS(0‒4 分制)提高 1 分和 PR-SMFIS(0‒10 分制)提高 3 分代表有临床意义的改善。

结论

PR-SMFRS 和 PR-SMFIS 是可靠且有效的工具,可分别评估 SMF 的严重程度和心理社会影响,并检测干预后的临床意义变化。

相似文献

1
Development and Validation of the Patient-Reported Submental Fat Rating Scale and the Patient-Reported Submental Fat Impact Scale.患者报告颏下脂肪分级量表和患者报告颏下脂肪影响量表的制定与验证。
Dermatol Surg. 2021 Apr 1;47(4):522-525. doi: 10.1097/DSS.0000000000002908.
2
Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study.ATX-101(脱氧胆酸),一种用于减少颏下多余脂肪的注射药物的疗效、患者报告结局及安全性概况:一项III期随机安慰剂对照研究的结果
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1707-15. doi: 10.1111/jdv.12377. Epub 2014 Mar 8.
3
Results from a pooled analysis of two European, randomized, placebo-controlled, phase 3 studies of ATX-101 for the pharmacologic reduction of excess submental fat.对两项欧洲的、随机的、安慰剂对照的3期研究进行汇总分析的结果,这些研究是关于ATX-101用于药物性减少颏下多余脂肪的。
Aesthetic Plast Surg. 2014 Oct;38(5):849-60. doi: 10.1007/s00266-014-0364-9. Epub 2014 Jul 2.
4
The Use of Deoxycholic Acid for the Clinical Reduction of Excess Submental Fat in Indian Patients.脱氧胆酸在印度患者中用于临床减少颏下多余脂肪的应用。
J Drugs Dermatol. 2019 Mar 1;18(3):266-272.
5
Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study.使用 ATX-101(脱氧胆酸)减少不必要的颏下脂肪:一项 III 期、随机、安慰剂对照研究的结果。
Br J Dermatol. 2014 Feb;170(2):445-53. doi: 10.1111/bjd.12695.
6
Efficacy and safety of the enzymatic mixture - Lipase, collagenase and hyaluronidase - In the treatment of moderate to severe submental fat: A prospective cohort study.酶混合物(脂肪酶、胶原酶和透明质酸酶)治疗中度至重度颏下脂肪的疗效与安全性:一项前瞻性队列研究
Heliyon. 2024 Feb 10;10(4):e25759. doi: 10.1016/j.heliyon.2024.e25759. eCollection 2024 Feb 29.
7
Submental fat reduction using sequential treatment approach with cryolipolysis and ATX-101.采用冷冻溶脂和 ATX-101 序贯治疗方法减少颏下脂肪。
J Cosmet Dermatol. 2022 Jun;21(6):2437-2444. doi: 10.1111/jocd.14909. Epub 2022 May 2.
8
A Double-Blind, Placebo-Controlled, Phase 3b Study of ATX-101 for Reduction of Mild or Extreme Submental Fat.一项评估 ATX-101 减少轻度或重度颏下脂肪的双盲、安慰剂对照、3b 期研究
Dermatol Surg. 2019 Dec;45(12):1531-1541. doi: 10.1097/DSS.0000000000001850.
9
Efficacy and safety of ATX-101 as a treatment for submental fullness: A retrospective analysis of two aesthetic practices.ATX-101 治疗颏下饱满的疗效和安全性:两项美容实践的回顾性分析。
J Cosmet Dermatol. 2020 Jun;19(6):1328-1332. doi: 10.1111/jocd.13165. Epub 2019 Sep 25.
10
ATX-101 for reduction of submental fat: A phase III randomized controlled trial.ATX-101 用于减少颏下脂肪:一项 III 期随机对照试验。
J Am Acad Dermatol. 2016 Oct;75(4):788-797.e7. doi: 10.1016/j.jaad.2016.04.028. Epub 2016 Jul 16.

引用本文的文献

1
A Prospective, Open-Label Study to Evaluate Dual-Modality Treatment With Deoxycholic Acid (ATX-101) and Hyaluronic Acid (VYC-20L) for Overall Improvement in Jawline Contour.一项评估脱氧胆酸(ATX-101)和透明质酸(VYC-20L)联合治疗对改善下颌轮廓整体效果的前瞻性、开放标签研究。
Aesthet Surg J Open Forum. 2025 Jun 28;7:ojaf081. doi: 10.1093/asjof/ojaf081. eCollection 2025.
2
CONTOUR Australia: Condition of Submental Fullness and Treatment Outcomes with Belkyra Registry.澳大利亚轮廓研究:颏下丰满状况及使用Belkyra的治疗结果登记研究
Plast Reconstr Surg Glob Open. 2023 Jul 18;11(7):e5123. doi: 10.1097/GOX.0000000000005123. eCollection 2023 Jul.